IN THIS ISSUE

Ed Silverman

Qsymia and Belviq can slow the progression of diabetes, but side effects and retail cost of about $200 per month are obstacles to formulary placement

Thomas Reinke

Emerging data show impressive results on glycemic control, but what about long-term results, safety, and high maintenance costs?

Peer-Reviewed
Angela K. Hochhalter, PhD
Rashmita Basu, PhD
Karim Prasla, PharmD
Managing Editor's Memo
Frank Diamond
Legislation & Regulation
John Carroll

Consumers expect reasonable premiums and copayments but give health plans grief over a proven cost-control method. How soon we forget.

Medication Management
Thomas Reinke

Management tactic borrowed from traditional pharmacy

Tomorrow's Medicine
Thomas Morrow, MD

Twenty-five years ago we had not even identified the virus that was neither type A nor type B. Now we have slowed its spread and can cure it, at considerable cost.

The Formulary Files
Krishna Rutvij Patel, PharmD
News & Commentary